A serine protease that catalyses the release of an N-terminal dipeptide. Several biologically-active peptides have been identified as dipeptidyl peptidase 4 substrates including INCRETINS; NEUROPEPTIDES; and CHEMOKINES. The protein is also found bound to ADENOSINE DEAMINASE on the T-CELL surface and is believed to play a role in T-cell activation.
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.
A subclass of exopeptidases that includes enzymes which cleave either two or three AMINO ACIDS from the end of a peptide chain.
A tricyclo bridged hydrocarbon.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
Pyrrolidines are saturated, heterocyclic organic compounds containing a five-membered ring with four carbon atoms and one nitrogen atom (NRCH2CH2), commonly found as structural components in various alkaloids and used in the synthesis of pharmaceuticals and other organic materials.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
A papain-like cysteine protease that has specificity for amino terminal dipeptides. The enzyme plays a role in the activation of several pro-inflammatory serine proteases by removal of their aminoterminal inhibitory dipeptides. Genetic mutations that cause loss of cathepsin C activity in humans are associated with PAPILLON-LEFEVRE DISEASE.
Glucose in blood.
Zinc-binding metalloproteases that are members of the type II integral membrane metalloproteases. They are expressed by GRANULOCYTES; MONOCYTES; and their precursors as well as by various non-hematopoietic cells. They release an N-terminal amino acid from a peptide, amide or arylamide.
EXOPEPTIDASES that specifically act on dipeptides. EC 3.4.13.
A gastrointestinal peptide hormone of about 43-amino acids. It is found to be a potent stimulator of INSULIN secretion and a relatively poor inhibitor of GASTRIC ACID secretion.
Pyrazines are heterocyclic organic compounds containing a six-membered ring with two nitrogen atoms at opposite positions, often responsible for the characteristic flavors and aromas found in various foods, beverages, and some biological systems, but they do not have a direct medical definition as they are not a drug, treatment, or a significant component of human physiology or pathology.
A phosphodiesterase 4 inhibitor with antidepressant properties.
A 33-amino acid peptide derived from the C-terminal of PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. It stimulates intestinal mucosal growth and decreased apoptosis of ENTEROCYTES. GLP-2 enhances gastrointestinal function and plays an important role in nutrient homeostasis.
Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
A subclass of EXOPEPTIDASES that act on the free N terminus end of a polypeptide liberating a single amino acid residue. EC 3.4.11.
An enzyme that catalyzes the hydrolysis of ADENOSINE to INOSINE with the elimination of AMMONIA.
Peptides composed of two amino acid units.
Minute projections of cell membranes which greatly increase the surface area of the cell.
A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS.
A group of ALKALOIDS, characterized by a nitrogen-containing necine, occurring mainly in plants of the BORAGINACEAE; COMPOSITAE; and LEGUMINOSAE plant families. They can be activated in the liver by hydrolysis of the ester and desaturation of the necine base to reactive electrophilic pyrrolic CYTOTOXINS.
Triazoles are a class of antifungal drugs that contain a triazole ring in their chemical structure and work by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting the integrity and function of the membrane.
Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Cell surface receptors that bind glucagon with high affinity and trigger intracellular changes which influence the behavior of cells. Activation of glucagon receptors causes a variety of effects; the best understood is the initiation of a complex enzymatic cascade in the liver which ultimately increases the availability of glucose to body organs.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Substances which lower blood glucose levels.
A monocyte chemoattractant protein that attracts MONOCYTES; LYMPHOCYTES; BASOPHILS; and EOSINOPHILS. Chemokine CCL8 has specificity for CCR3 RECEPTORS and CCR5 RECEPTORS.
A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.
Compounds that specifically inhibit PHOSPHODIESTERASE 4.
Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx.
Pentanoic acid, also known as valeric acid, is a carboxylic acid with a 5-carbon chain (C5H10O2), having a distinctive pungent and rancid odor, found in some animals' sweat, certain foods, and produced through wood fermentation.
F344 rats are an inbred strain of albino laboratory rats (Rattus norvegicus) that have been widely used in biomedical research due to their consistent and reliable genetic background, which facilitates the study of disease mechanisms and therapeutic interventions.
A class of enzymes that catalyzes the degradation of gelatin by acting on the peptide bonds. EC 3.4.24.-.
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed)
A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.
A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.
Thiazoles are heterocyclic organic compounds containing a sulfur atom and a nitrogen atom, which are bound by two carbon atoms to form a five-membered ring, and are widely found in various natural and synthetic substances, including some pharmaceuticals and vitamins.
Peptides composed of between two and twelve amino acids.
An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes.
A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.
A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511)
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg).
Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP.
Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.
The rate dynamics in chemical or physical systems.
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
The process of cleaving a chemical compound by the addition of a molecule of water.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
Two populations of Zucker rats have been cited in research--the "fatty" or obese and the lean. The "fatty" rat (Rattus norvegicus) appeared as a spontaneous mutant. The obese condition appears to be due to a single recessive gene.

Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. (1/305)

PURPOSE: CD26 is a 110-kDa cell surface glycoprotein with a role in tumor development through its association with key intracellular proteins. In this report, we show that binding of soluble anti-CD26 monoclonal antibody (mAb) inhibits the growth of the human renal carcinoma cells in both in vitro and in vivo experiments. EXPERIMENTAL DESIGN: Growth inhibition by anti-CD26 mAb was assessed using proliferation assay and cell cycle analysis. Anti-CD26 mAb, chemical inhibitors, dominant-negative, or constitutively active forms of specific signaling molecules were used to evaluate CD26-associated pathways. The in vivo growth-inhibitory effect of anti-CD26 mAb was also assessed in a human renal carcinoma mouse xenograft model. RESULTS: In vitro experiments show that anti-CD26 mAb induces G1-S cell cycle arrest associated with enhanced p27(kip1) expression, down-regulation of cyclin-dependent kinase 2, and dephosphorylation of retinoblastoma substrate. Moreover, our data show that enhanced p27(kip1) expression is dependent on the attenuation of Akt activity. Anti-CD26 mAb also internalizes cell surface CD26, leading to decreased binding to collagen and fibronectin. Experiments with a mouse xenograft model involving human renal carcinoma cells show that anti-CD26 mAb treatment drastically inhibits tumor growth in tumor-bearing mice, resulting in enhanced survival. CONCLUSIONS: Taken together, our data strongly suggest that anti-CD26 mAb treatment may have potential clinical use for CD26-positive renal cell carcinomas.  (+info)

Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. (2/305)

Acne is a chronic disease hallmarked by sebaceous hyperplasia, follicular hyperkeratosis, and inflammation. Parallel targeting of these factors is required to treat acne effectively. Inhibitors of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) show strong anti-inflammatory effects on immune cells and therapeutic efficacy in autoimmune disorders. Our investigation focused on the expression and functional relevance of these ectopeptidases in three cell types which exhibit an altered phenotype in early acne lesions. We showed for the first time expression of DP IV and APN on human sebocytes. In the SZ95 sebocyte cell line, the DP IV inhibitors Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyrrolidide and the APN inhibitors actinonin and bestatin suppressed proliferation, enhanced terminal differentiation, and slightly decreased total neutral lipid production. The anti-inflammatory and differentiation-restoring cytokine IL-1 receptor antagonist was significantly upregulated in SZ95 sebocytes and the HaCaT keratinocyte cell line in the presence of inhibitors. Furthermore, the inhibitors suppressed proliferation and IL-2 production of Propionibacterium acnes-stimulated T cells ex vivo and enhanced the expression of the immunosuppressive cytokine transforming growth factor-beta1. Our data provide first evidence for a functional role of DP IV and APN in the sebaceous gland apparatus and for their inhibitors, used alone or in combination, as completely new substances possibly affecting acne pathogenesis in a therapeutic manner.  (+info)

CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. (3/305)

In utero hematopoietic-cell transplantation (IUHCT) can induce donor-specific tolerance to facilitate postnatal transplantation. Induction of tolerance requires a threshold level of mixed hematopoietic chimerism. CD26 is a peptidase whose inhibition increases homing and engraftment of hematopoietic cells in postnatal transplantation. We hypothesized that CD26 inhibition would increase donor-cell homing to the fetal liver (FL) and improve allogeneic engraftment following IUHCT. To evaluate this hypothesis, B6GFP bone marrow (BM) or enriched hematopoietic stem cells (HSCs) were transplanted into allogeneic fetal mice with or without CD26 inhibition. Recipients were analyzed for FL homing and peripheral-blood chimerism from 4 to 28 weeks of life. We found that CD26 inhibition of donor cells results in (1) increased homing of allogeneic BM and HSCs to the FL, (2) an increased number of injected animals with evidence of postnatal engraftment, (3) increased donor chimerism levels following IUHCT, and (4) a competitive engraftment advantage over noninhibited congenic donor cells. This study supports CD26 inhibition as a potential method to increase the level of FL homing and engraftment following IUHCT. The resulting increased donor chimerism suggests that CD26 inhibition may in the future be used as a method of increasing donor-specific tolerance following IUHCT.  (+info)

What are incretins, and how will they influence the management of type 2 diabetes? (4/305)

OBJECTIVE: To review the pathophysiology of type 2 diabetes (T2DM), the role of incretins, the potential of incretin-based therapies to address unmet therapeutic needs in T2DM, and the potential impact this will have on the contribution of managed care pharmacy to diabetes therapy. SUMMARY: Diabetes, the fifth leading cause of death by disease in the United States, costs approximately $132 billion per year in direct and indirect medical expenses. According to the Centers for Disease Control and Prevention.s National Health and Nutrition Examination Survey, a majority of diabetes patients do not achieve target A1C levels with their current treatment regimens. Advances in understanding the pathophysiologic abnormalities underlying the metabolic dysfunctions associated with T2DM are leading to the development of new treatment approaches and new therapeutic classes of drugs. Novel incretin-based therapies currently available, and in late-stage development, are among those showing the greatest promise for addressing the unmet needs of traditional therapies.  (+info)

Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats. (5/305)

Several combination therapies have been tried for treating of type 2 diabetes to control more effectively fasting hyperglycemia and postprandial hyperglycemia. In this study, we have examined the effects of combining a novel, selective, and competitive dipeptidyl peptidase IV (DPP-IV) inhibitor, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-o ne tosylate (E3024), with a representative of one of two types of insulin secretagogues, i.e., either glybenclamide (a sulfonylurea) or nateglinide (a rapid-onset/short-duration insulin secretagogue), on glucose and insulin levels in an oral glucose tolerance test (OGTT) using mice fed a high-fat diet. In addition, we have investigated the effects of these combinations on blood glucose levels in fasting rats. Two-way analysis of variance showed that the combination of E3024 and glybenclamide improved glucose tolerance additively and also caused a synergistic increase in insulin levels in the OGTT in mice fed a high-fat diet. In a similar way, the combination of E3024 and nateglinide ameliorated glucose tolerance additively and raised insulin levels additively. In fasting rats, coadministration of E3024 with glybenclamide or nateglinide treatment did not affect the glucose-lowering effects of the insulin secretagogues. Therefore, a DPP-IV inhibitor in combination with glybenclamide or nateglinide may be a promising option for the treatment of type 2 diabetes, and particularly, for controlling postprandial hyperglycemia in the clinic.  (+info)

Identification and partial characterization of the enzyme of omega: one of five putative DPP IV genes in Drosophila melanogaster. (6/305)

The omega (ome) gene product is a modifier of larval cuticle protein 5 and its alleles (and duplicates) in the third instar of Drosophila melanogaster. Using deletion mapping the locus mapped to 70F-71A on the left arm of chromosome 3. A homozygote null mutant (ome 1) shows a pleiotropic phenotype that affected the size, developmental time of the flies, and the fertility (or perhaps the behavior) of homozygous mutant males. The omega gene was verified as producing a dipeptidyl peptidase IV (DPPIV) by genetic analysis, substrate specificity and pH optimum. The identity of the gene was confirmed as CG32145 (cytology 70F4) in the Celera Database (Berkeley Drosophila Genome Project), which is consistent with its deletion map position. The genomic structure of the gene is described and the decrease in DPPIV activity in the mutant ome1 is shown to be due to the gene CG32145 (omega). The D. melanogaster omega DPPIV enzyme was partially purified and characterized. The exons of the ome1 mutant were sequenced and a base substitution mutation in exon 4 was identified that would yield a truncated protein caused by a stop codon. A preliminary study of the compartmentalization of the omega DPPIV enzyme in several organs is also reported.  (+info)

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. (7/305)

Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPP IV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or 'gliptins') have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.  (+info)

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. (8/305)

The metabolism and excretion of [(14)C]sitagliptin, an orally active, potent and selective dipeptidyl peptidase 4 inhibitor, were investigated in humans after a single oral dose of 83 mg/193 muCi. Urine, feces, and plasma were collected at regular intervals for up to 7 days. The primary route of excretion of radioactivity was via the kidneys, with a mean value of 87% of the administered dose recovered in urine. Mean fecal excretion was 13% of the administered dose. Parent drug was the major radioactive component in plasma, urine, and feces, with only 16% of the dose excreted as metabolites (13% in urine and 3% in feces), indicating that sitagliptin was eliminated primarily by renal excretion. Approximately 74% of plasma AUC of total radioactivity was accounted for by parent drug. Six metabolites were detected at trace levels, each representing <1 to 7% of the radioactivity in plasma. These metabolites were the N-sulfate and N-carbamoyl glucuronic acid conjugates of parent drug, a mixture of hydroxylated derivatives, an ether glucuronide of a hydroxylated metabolite, and two metabolites formed by oxidative desaturation of the piperazine ring followed by cyclization. These metabolites were detected also in urine, at low levels. Metabolite profiles in feces were similar to those in urine and plasma, except that the glucuronides were not detected in feces. CYP3A4 was the major cytochrome P450 isozyme responsible for the limited oxidative metabolism of sitagliptin, with some minor contribution from CYP2C8.  (+info)

Dipeptidyl peptidase 4 (DPP-4) is a serine protease enzyme that is widely distributed in various tissues and organs, including the kidney, liver, intestines, and immune cells. It plays a crucial role in regulating several biological processes, such as glucose metabolism, immune function, and cell signaling.

In terms of glucose metabolism, DPP-4 is responsible for breaking down incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are released from the gut in response to food intake. These hormones stimulate insulin secretion from pancreatic beta cells, suppress glucagon release, and promote satiety, thereby helping to regulate blood sugar levels. By degrading GLP-1 and GIP, DPP-4 reduces their activity and contributes to the development of type 2 diabetes.

DPP-4 inhibitors are a class of drugs used to treat type 2 diabetes by blocking the action of DPP-4 and increasing incretin hormone levels, leading to improved insulin secretion and glucose control.

Dipeptidyl-Peptidase IV (DPP-4) inhibitors are a class of medications used to treat type 2 diabetes. They work by increasing the levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), which help regulate blood sugar levels in the body.

Incretin hormones are released from the gut in response to food intake and promote insulin secretion, suppress glucagon secretion, slow down gastric emptying, and reduce appetite. However, these hormones are rapidly degraded by the enzyme DPP-4, which reduces their effectiveness.

DPP-4 inhibitors block the action of this enzyme, thereby increasing the levels of incretin hormones in the body and enhancing their effects on blood sugar control. Some examples of DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin.

These medications are usually taken orally once or twice a day and are often used in combination with other diabetes medications, such as metformin or sulfonylureas, to achieve better blood sugar control. Common side effects of DPP-4 inhibitors include upper respiratory tract infections, headache, and nasopharyngitis (inflammation of the throat and nasal passages).

Dipeptidyl-peptidases (DPPs) and tripeptidyl-peptidases (TPPs) are two types of enzymes that belong to the class of peptidases, which are proteins that help break down other proteins into smaller peptides or individual amino acids.

Dipeptidyl-peptidases cleave dipeptides (two-amino acid units) from the N-terminus (the end with a free amino group) of polypeptides and proteins, while tripeptidyl-peptidases cleave tripeptides (three-amino acid units) from the same location.

There are several different isoforms of DPPs and TPPs that have been identified in various organisms, including humans. These enzymes play important roles in regulating various physiological processes, such as digestion, immune function, and blood glucose homeostasis.

Inhibitors of DPP-4, one specific isoform of DPPs, have been developed for the treatment of type 2 diabetes, as they help increase the levels of incretin hormones that stimulate insulin secretion and suppress glucagon production.

Adamantane is a chemical compound with the formula C10H16. It is a hydrocarbon that consists of a cage-like structure of carbon atoms, making it one of the simplest diamondoid compounds. The term "adamantane" is also used more broadly to refer to any compound that contains this characteristic carbon cage structure.

In the context of medicine, adamantane derivatives are a class of antiviral drugs that have been used to treat and prevent influenza A infections. These drugs work by binding to the M2 protein of the influenza virus, which is essential for viral replication. By blocking the function of this protein, adamantane derivatives can prevent the virus from multiplying within host cells.

Examples of adamantane derivatives used in medicine include amantadine and rimantadine. These drugs are typically administered orally and have been shown to be effective at reducing the severity and duration of influenza A symptoms, particularly when used early in the course of infection. However, resistance to these drugs has become increasingly common among circulating strains of influenza A virus, which has limited their usefulness in recent years.

Glucagon-like peptide 1 (GLP-1) is a hormone that is secreted by the intestines in response to food intake. It plays a crucial role in regulating blood sugar levels through several mechanisms, including stimulation of insulin secretion from the pancreas, inhibition of glucagon release, slowing gastric emptying, and promoting satiety. GLP-1 is an important target for the treatment of type 2 diabetes due to its insulin-secretory and glucose-lowering effects. In addition, GLP-1 receptor agonists are used in the management of obesity due to their ability to promote weight loss by reducing appetite and increasing feelings of fullness.

Pyrrolidines are not a medical term per se, but they are a chemical compound that can be encountered in the field of medicine and pharmacology. Pyrrolidine is an organic compound with the molecular formula (CH2)4NH. It is a cyclic secondary amine, which means it contains a nitrogen atom surrounded by four carbon atoms in a ring structure.

Pyrrolidines can be found in certain natural substances and are also synthesized for use in pharmaceuticals and research. They have been used as building blocks in the synthesis of various drugs, including some muscle relaxants, antipsychotics, and antihistamines. Additionally, pyrrolidine derivatives can be found in certain plants and fungi, where they may contribute to biological activity or toxicity.

It is important to note that while pyrrolidines themselves are not a medical condition or diagnosis, understanding their chemical properties and uses can be relevant to the study and development of medications.

Protease inhibitors are a class of antiviral drugs that are used to treat infections caused by retroviruses, such as the human immunodeficiency virus (HIV), which is responsible for causing AIDS. These drugs work by blocking the activity of protease enzymes, which are necessary for the replication and multiplication of the virus within infected cells.

Protease enzymes play a crucial role in the life cycle of retroviruses by cleaving viral polyproteins into functional units that are required for the assembly of new viral particles. By inhibiting the activity of these enzymes, protease inhibitors prevent the virus from replicating and spreading to other cells, thereby slowing down the progression of the infection.

Protease inhibitors are often used in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS. Common examples of protease inhibitors include saquinavir, ritonavir, indinavir, and atazanavir. While these drugs have been successful in improving the outcomes of people living with HIV/AIDS, they can also cause side effects such as nausea, diarrhea, headaches, and lipodystrophy (changes in body fat distribution).

Cathepsin C is a lysosomal cysteine protease that plays a role in intracellular protein degradation and activation of other proteases. It is also known as dipeptidyl peptidase I (DPP I) because of its ability to remove dipeptides from the N-terminus of polypeptides. Cathepsin C is widely expressed in many tissues, including immune cells, and has been implicated in various physiological and pathological processes such as antigen presentation, bone resorption, and tumor cell invasion. Defects in the gene encoding cathepsin C have been associated with several genetic disorders, including Papillon-Lefèvre syndrome and Haim-Munk syndrome, which are characterized by severe periodontal disease and skin abnormalities.

Blood glucose, also known as blood sugar, is the concentration of glucose in the blood. Glucose is a simple sugar that serves as the main source of energy for the body's cells. It is carried to each cell through the bloodstream and is absorbed into the cells with the help of insulin, a hormone produced by the pancreas.

The normal range for blood glucose levels in humans is typically between 70 and 130 milligrams per deciliter (mg/dL) when fasting, and less than 180 mg/dL after meals. Levels that are consistently higher than this may indicate diabetes or other metabolic disorders.

Blood glucose levels can be measured through a variety of methods, including fingerstick blood tests, continuous glucose monitoring systems, and laboratory tests. Regular monitoring of blood glucose levels is important for people with diabetes to help manage their condition and prevent complications.

CD13, also known as aminopeptidase N, is a type of protein found on the surface of some cells in the human body. It is a type of antigen, which is a molecule that can trigger an immune response when recognized by the immune system. CD13 is found on the surface of various cell types, including certain white blood cells and cells that line the blood vessels. It plays a role in several biological processes, such as breaking down proteins and regulating inflammation.

CD13 is also a target for some cancer therapies because it is overexpressed in certain types of cancer cells. For example, CD13-targeted therapies have been developed to treat acute myeloid leukemia (AML), a type of blood cancer that affects the bone marrow. These therapies work by binding to CD13 on the surface of AML cells and triggering an immune response that helps to destroy the cancer cells.

It's important to note that while CD13 is an antigen, it is not typically associated with infectious diseases or foreign invaders, as other antigens might be. Instead, it is a normal component of human cells that can play a role in various physiological processes and disease states.

Dipeptidases are a group of enzymes that break down dipeptides, which are composed of two amino acids joined by a peptide bond. These enzymes catalyze the hydrolysis of dipeptides into individual amino acids, helping to facilitate their absorption and utilization in the body. Dipeptidases can be found on the brush border membrane of the small intestine, as well as in various tissues and organs, such as the kidneys, liver, and pancreas. They play a crucial role in protein metabolism and maintaining amino acid homeostasis within the body.

Gastric Inhibitory Polypeptide (GIP) is a 42-amino acid long peptide hormone that is released from the K cells in the duodenum and jejunum of the small intestine in response to food intake, particularly carbohydrates and fats. It is also known as glucose-dependent insulinotropic polypeptide.

GIP has several physiological effects on the body, including:

* Incretin effect: GIP stimulates the release of insulin from the pancreas in a glucose-dependent manner, which means that it only increases insulin secretion when blood glucose levels are high. This is known as the incretin effect and helps to regulate postprandial glucose levels.
* Inhibition of gastric acid secretion: GIP inhibits the release of gastric acid from the stomach, which helps to protect the intestinal mucosa from damage caused by excessive acid production.
* Increase in blood flow: GIP increases blood flow to the intestines, which helps to facilitate nutrient absorption.
* Energy storage: GIP promotes the storage of energy by increasing fat synthesis and reducing fat breakdown in adipose tissue.

Overall, GIP plays an important role in regulating glucose metabolism, energy balance, and gastrointestinal function.

I'm sorry for any confusion, but "pyrazines" is not a term commonly used in medical definitions. Pyrazines are actually a class of organic compounds that contain a ring made up of two nitrogen atoms and three carbon atoms. They are found in various foods and contribute to their flavors. If you have any questions about organic chemistry or food science, I'd be happy to try to help!

Rolipram is not a medical term per se, but it is the name of a pharmaceutical compound. Rolipram is a selective inhibitor of phosphodiesterase-4 (PDE4), an enzyme that plays a role in regulating the body's inflammatory response and is involved in various cellular signaling pathways.

Rolipram has been investigated as a potential therapeutic agent for several medical conditions, including depression, asthma, chronic obstructive pulmonary disease (COPD), and Alzheimer's disease. However, its development as a drug has been hindered by issues related to its pharmacokinetics, such as poor bioavailability and a short half-life, as well as side effects like nausea and emesis.

Therefore, while Rolipram is an important compound in the field of pharmacology and has contributed significantly to our understanding of PDE4's role in various physiological processes, it is not typically used as a medical term to describe a specific disease or condition.

Glucagon-like peptide 2 (GLP-2) is a hormone that is produced in the intestines by the enteroendocrine L cells. It is a 33-amino acid peptide that is derived from the preproglucagon gene and has a variety of effects on the gastrointestinal system, including increasing nutrient absorption, stimulating intestinal growth, and reducing gut permeability.

GLP-2 acts by binding to its receptor, which is found on the surface of intestinal epithelial cells, as well as on blood vessels and immune cells in the gut. Activation of the GLP-2 receptor leads to a variety of intracellular signaling pathways that promote cell survival, proliferation, and differentiation.

In addition to its role in normal intestinal function, GLP-2 has been investigated as a potential therapeutic agent for various gastrointestinal disorders, including short bowel syndrome, inflammatory bowel disease, and intestinal injury. Synthetic GLP-2 agonists have been developed and are currently being studied in clinical trials for these indications.

Serine endopeptidases are a type of enzymes that cleave peptide bonds within proteins (endopeptidases) and utilize serine as the nucleophilic amino acid in their active site for catalysis. These enzymes play crucial roles in various biological processes, including digestion, blood coagulation, and programmed cell death (apoptosis). Examples of serine endopeptidases include trypsin, chymotrypsin, thrombin, and elastase.

Glucagon-like peptides (GLPs) are hormones that are produced in the intestines in response to food consumption. They belong to a class of hormones known as incretins, which play a role in regulating blood sugar levels by stimulating the pancreas to produce insulin and inhibiting the release of glucagon.

There are two main types of GLPs: GLP-1 and GLP-2. GLP-1 is secreted in response to meals and stimulates the pancreas to produce insulin, suppresses glucagon production, slows gastric emptying, and promotes satiety. GLP-2, on the other hand, promotes intestinal growth and improves nutrient absorption.

GLP-1 receptor agonists are a class of medications used to treat type 2 diabetes. They mimic the effects of natural GLP-1 by stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. These medications have been shown to improve blood sugar control, reduce body weight, and lower the risk of cardiovascular events in people with type 2 diabetes.

Aminopeptidases are a group of enzymes that catalyze the removal of amino acids from the N-terminus of polypeptides and proteins. They play important roles in various biological processes, including protein degradation, processing, and activation. Aminopeptidases are classified based on their specificity for different types of amino acids and the mechanism of their action. Some of the well-known aminopeptidases include leucine aminopeptidase, alanyl aminopeptidase, and arginine aminopeptidase. They are widely distributed in nature and found in various tissues and organisms, including bacteria, plants, and animals. In humans, aminopeptidases are involved in several physiological functions, such as digestion, immune response, and blood pressure regulation.

Adenosine Deaminase (ADA) is an enzyme that plays a crucial role in the immune system by helping to regulate the levels of certain chemicals called purines within cells. Specifically, ADA helps to break down adenosine, a type of purine, into another compound called inosine. This enzyme is found in all tissues of the body, but it is especially active in the immune system's white blood cells, where it helps to support their growth, development, and function.

ADA deficiency is a rare genetic disorder that can lead to severe combined immunodeficiency (SCID), a condition in which babies are born with little or no functional immune system. This makes them extremely vulnerable to infections, which can be life-threatening. ADA deficiency can be treated with enzyme replacement therapy, bone marrow transplantation, or gene therapy.

A dipeptide is a type of molecule that is formed by the condensation of two amino acids. In this process, the carboxyl group (-COOH) of one amino acid combines with the amino group (-NH2) of another amino acid, releasing a water molecule and forming a peptide bond.

The resulting molecule contains two amino acids joined together by a single peptide bond, which is a type of covalent bond that forms between the carboxyl group of one amino acid and the amino group of another. Dipeptides are relatively simple molecules compared to larger polypeptides or proteins, which can contain hundreds or even thousands of amino acids linked together by multiple peptide bonds.

Dipeptides have a variety of biological functions in the body, including serving as building blocks for larger proteins and playing important roles in various physiological processes. Some dipeptides also have potential therapeutic uses, such as in the treatment of hypertension or muscle wasting disorders.

Microvilli are small, finger-like projections that line the apical surface (the side facing the lumen) of many types of cells, including epithelial and absorptive cells. They serve to increase the surface area of the cell membrane, which in turn enhances the cell's ability to absorb nutrients, transport ions, and secrete molecules.

Microvilli are typically found in high density and are arranged in a brush-like border called the "brush border." They contain a core of actin filaments that provide structural support and allow for their movement and flexibility. The membrane surrounding microvilli contains various transporters, channels, and enzymes that facilitate specific functions related to absorption and secretion.

In summary, microvilli are specialized structures on the surface of cells that enhance their ability to interact with their environment by increasing the surface area for transport and secretory processes.

Endopeptidases are a type of enzyme that breaks down proteins by cleaving peptide bonds inside the polypeptide chain. They are also known as proteinases or endoproteinases. These enzymes work within the interior of the protein molecule, cutting it at specific points along its length, as opposed to exopeptidases, which remove individual amino acids from the ends of the protein chain.

Endopeptidases play a crucial role in various biological processes, such as digestion, blood coagulation, and programmed cell death (apoptosis). They are classified based on their catalytic mechanism and the structure of their active site. Some examples of endopeptidase families include serine proteases, cysteine proteases, aspartic proteases, and metalloproteases.

It is important to note that while endopeptidases are essential for normal physiological functions, they can also contribute to disease processes when their activity is unregulated or misdirected. For instance, excessive endopeptidase activity has been implicated in the pathogenesis of neurodegenerative disorders, cancer, and inflammatory conditions.

Pyrrolizidine alkaloids (PAs) are a group of naturally occurring chemical compounds found in various plants, particularly in the families Boraginaceae, Asteraceae, and Fabaceae. These compounds have a pyrrolizidine ring structure and can be toxic or carcinogenic to humans and animals. They can contaminate food and feed sources, leading to poisoning and health issues. Chronic exposure to PAs has been linked to liver damage, veno-occlusive disease, and cancer. It is important to avoid consumption of plants containing high levels of PAs and to monitor food and feed sources for PA contamination.

Triazoles are a class of antifungal medications that have broad-spectrum activity against various fungi, including yeasts, molds, and dermatophytes. They work by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, leading to increased permeability and disruption of fungal growth. Triazoles are commonly used in both systemic and topical formulations for the treatment of various fungal infections, such as candidiasis, aspergillosis, cryptococcosis, and dermatophytoses. Some examples of triazole antifungals include fluconazole, itraconazole, voriconazole, and posaconazole.

Phosphodiesterase inhibitors (PDE inhibitors) are a class of drugs that work by blocking the action of phosphodiesterase enzymes, which are responsible for breaking down cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), two crucial intracellular signaling molecules.

By inhibiting these enzymes, PDE inhibitors increase the concentration of cAMP and cGMP in the cells, leading to a variety of effects depending on the specific type of PDE enzyme that is inhibited. These drugs have been used in the treatment of various medical conditions such as erectile dysfunction, pulmonary arterial hypertension, and heart failure.

Examples of PDE inhibitors include sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra) for erectile dysfunction, and iloprost, treprostinil, and sildenafil for pulmonary arterial hypertension. It's important to note that different PDE inhibitors have varying levels of selectivity for specific PDE isoforms, which can result in different therapeutic effects and side effect profiles.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Glucagon receptors are a type of G protein-coupled receptor found on the surface of cells in the body, particularly in the liver, fat, and muscle tissues. These receptors bind to the hormone glucagon, which is produced and released by the alpha cells of the pancreas in response to low blood sugar levels (hypoglycemia).

When glucagon binds to its receptor, it triggers a series of intracellular signaling events that lead to the breakdown of glycogen (a stored form of glucose) in the liver and the release of glucose into the bloodstream. This helps to raise blood sugar levels back to normal.

Glucagon receptors also play a role in regulating fat metabolism, as activation of these receptors in adipose tissue can stimulate the breakdown of triglycerides (a type of fat) into free fatty acids and glycerol, which can then be used as energy sources.

Abnormalities in glucagon receptor function or expression have been implicated in various metabolic disorders, including diabetes and obesity.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Hypoglycemic agents are a class of medications that are used to lower blood glucose levels in the treatment of diabetes mellitus. These medications work by increasing insulin sensitivity, stimulating insulin release from the pancreas, or inhibiting glucose production in the liver. Examples of hypoglycemic agents include sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. It's important to note that the term "hypoglycemic" refers to a condition of abnormally low blood glucose levels, but in this context, the term is used to describe agents that are used to treat high blood glucose levels (hyperglycemia) associated with diabetes.

Chemokine (C-C motif) ligand 8, also known as CCL8 or MCP-2 (monocyte chemoattractant protein-2), is a small signaling protein that belongs to the CC chemokine family. Chemokines are a group of cytokines, or cell signaling molecules, that play a crucial role in immune responses and inflammation by recruiting immune cells to sites of infection or injury.

CCL8 is produced by various cell types, including monocytes, macrophages, dendritic cells, and endothelial cells. It exerts its effects by binding to chemokine receptors, particularly CCR1, CCR2, CCR3, and CCR5, which are expressed on the surface of various immune cells such as monocytes, T cells, eosinophils, and basophils.

CCL8 is involved in several physiological and pathological processes, including:

1. Chemotaxis: It attracts immune cells to the site of inflammation or infection by inducing their migration through a concentration gradient.
2. Immune cell activation: CCL8 can activate immune cells, promoting their proliferation, differentiation, and effector functions.
3. Inflammatory responses: By recruiting immune cells to sites of injury or infection, CCL8 contributes to the development of inflammation.
4. Viral infections: CCL8 has been implicated in the recruitment of immune cells during viral infections, such as HIV and HCV.
5. Cancer: CCL8 may contribute to tumor progression by promoting angiogenesis, recruiting immunosuppressive cells, and enhancing cancer cell migration and invasion.

Abnormal regulation of CCL8 has been associated with various diseases, including inflammatory disorders, infections, and cancer.

Substrate specificity in the context of medical biochemistry and enzymology refers to the ability of an enzyme to selectively bind and catalyze a chemical reaction with a particular substrate (or a group of similar substrates) while discriminating against other molecules that are not substrates. This specificity arises from the three-dimensional structure of the enzyme, which has evolved to match the shape, charge distribution, and functional groups of its physiological substrate(s).

Substrate specificity is a fundamental property of enzymes that enables them to carry out highly selective chemical transformations in the complex cellular environment. The active site of an enzyme, where the catalysis takes place, has a unique conformation that complements the shape and charge distribution of its substrate(s). This ensures efficient recognition, binding, and conversion of the substrate into the desired product while minimizing unwanted side reactions with other molecules.

Substrate specificity can be categorized as:

1. Absolute specificity: An enzyme that can only act on a single substrate or a very narrow group of structurally related substrates, showing no activity towards any other molecule.
2. Group specificity: An enzyme that prefers to act on a particular functional group or class of compounds but can still accommodate minor structural variations within the substrate.
3. Broad or promiscuous specificity: An enzyme that can act on a wide range of structurally diverse substrates, albeit with varying catalytic efficiencies.

Understanding substrate specificity is crucial for elucidating enzymatic mechanisms, designing drugs that target specific enzymes or pathways, and developing biotechnological applications that rely on the controlled manipulation of enzyme activities.

Phosphodiesterase 4 inhibitors (PDE4 inhibitors) are a class of drugs that work by increasing the levels of cyclic adenosine monophosphate (cAMP) in cells. They do this by blocking the phosphodiesterase 4 enzyme, which is responsible for breaking down cAMP.

Cyclic AMP is an important intracellular signaling molecule that plays a role in various physiological processes, including inflammation and immune response. By increasing cAMP levels, PDE4 inhibitors can help to reduce inflammation and modulate the immune system.

PDE4 inhibitors have been studied for their potential therapeutic benefits in a range of conditions, including asthma, COPD, psoriasis, atopic dermatitis, and depression. Some examples of PDE4 inhibitors include roflumilast, apremilast, crisaborole, and ditropan.

It's important to note that while PDE4 inhibitors have shown promise in clinical trials, they can also have side effects, such as gastrointestinal symptoms, headache, and dizziness. Additionally, their long-term safety and efficacy are still being studied.

Angioedema is a medical condition characterized by rapid swelling of the skin, mucous membranes, and submucosal tissues. The swelling typically occurs in the face, lips, tongue, larynx, and extremities, and can also affect the gastrointestinal tract. Angioedema can be caused by a variety of factors, including allergic reactions, hereditary genetic mutations, and certain medications.

In medical terms, angioedema is defined as a self-limiting episode of localized edema in the deep dermis, subcutaneous tissue, or mucous membranes, characterized by well-circumscribed, nonpitting, nondependent swelling. The swelling can occur suddenly and may persist for up to 72 hours. In severe cases, angioedema can cause airway obstruction and be life-threatening if not treated promptly.

Angioedema can be classified into two main types: allergic or non-allergic. Allergic angioedema is caused by an immune response to an allergen, such as food, medication, or insect venom. Non-allergic angioedema can be further divided into several subtypes, including hereditary angioedema (HA), acquired angioedema (AAE), and drug-induced angioedema.

Hereditary angioedema is a rare genetic disorder caused by mutations in the C1 inhibitor gene, leading to uncontrolled activation of the complement system and increased production of bradykinin, a potent vasodilator. Acquired angioedema is similar to hereditary angioedema but occurs later in life and is associated with underlying medical conditions such as lymphoproliferative disorders or autoimmune diseases. Drug-induced angioedema can be caused by a variety of medications, including ACE inhibitors, angiotensin receptor blockers (ARBs), and nonsteroidal anti-inflammatory drugs (NSAIDs).

The diagnosis of angioedema is typically based on clinical presentation, medical history, and laboratory tests. Treatment depends on the underlying cause of the condition but may include antihistamines, corticosteroids, epinephrine, and medications that target the complement system or bradykinin pathway. In severe cases, hospitalization and intensive care may be necessary to manage airway obstruction and other complications.

I am sorry for any confusion, but "Pentanoic Acids" is not a recognized medical term or concept. Pentanoic acid, also known as valeric acid, is an organic compound with the formula CH3CH2CH2CH2CO2H. It is a fatty acid with five carbon atoms, and it may have some uses in industry, but it does not have specific relevance to medical definition or healthcare.

F344 is a strain code used to designate an outbred stock of rats that has been inbreeded for over 100 generations. The F344 rats, also known as Fischer 344 rats, were originally developed at the National Institutes of Health (NIH) and are now widely used in biomedical research due to their consistent and reliable genetic background.

Inbred strains, like the F344, are created by mating genetically identical individuals (siblings or parents and offspring) for many generations until a state of complete homozygosity is reached, meaning that all members of the strain have identical genomes. This genetic uniformity makes inbred strains ideal for use in studies where consistent and reproducible results are important.

F344 rats are known for their longevity, with a median lifespan of around 27-31 months, making them useful for aging research. They also have a relatively low incidence of spontaneous tumors compared to other rat strains. However, they may be more susceptible to certain types of cancer and other diseases due to their inbred status.

It's important to note that while F344 rats are often used as a standard laboratory rat strain, there can still be some genetic variation between individual animals within the same strain, particularly if they come from different suppliers or breeding colonies. Therefore, it's always important to consider the source and history of any animal model when designing experiments and interpreting results.

Gelatinases are a group of matrix metalloproteinases (MMPs) that have the ability to degrade gelatin, which is denatured collagen. There are two main types of gelatinases: MMP-2 (gelatinase A) and MMP-9 (gelatinase B). These enzymes play important roles in various physiological processes such as tissue remodeling and wound healing, but they have also been implicated in several pathological conditions, including cancer, cardiovascular diseases, and neurological disorders.

MMP-2 is produced by a variety of cells, including fibroblasts, endothelial cells, and immune cells. It plays a crucial role in angiogenesis (the formation of new blood vessels) and tumor cell invasion and metastasis. MMP-9 is primarily produced by inflammatory cells such as neutrophils and macrophages, and it has been associated with the degradation of the extracellular matrix during inflammation and tissue injury.

Both MMP-2 and MMP-9 are synthesized as inactive zymogens and require activation by other proteases or physicochemical factors before they can exert their enzymatic activity. The regulation of gelatinase activity is tightly controlled at multiple levels, including gene expression, protein synthesis, secretion, activation, and inhibition. Dysregulation of gelatinase activity has been linked to various diseases, making them attractive targets for therapeutic intervention.

Nitriles, in a medical context, refer to a class of organic compounds that contain a cyano group (-CN) bonded to a carbon atom. They are widely used in the chemical industry and can be found in various materials, including certain plastics and rubber products.

In some cases, nitriles can pose health risks if ingested, inhaled, or come into contact with the skin. Short-term exposure to high levels of nitriles can cause irritation to the eyes, nose, throat, and respiratory tract. Prolonged or repeated exposure may lead to more severe health effects, such as damage to the nervous system, liver, and kidneys.

However, it's worth noting that the medical use of nitriles is not very common. Some nitrile gloves are used in healthcare settings due to their resistance to many chemicals and because they can provide a better barrier against infectious materials compared to latex or vinyl gloves. But beyond this application, nitriles themselves are not typically used as medications or therapeutic agents.

Pyrrolidinones are a class of organic compounds that contain a pyrrolidinone ring, which is a five-membered ring containing four carbon atoms and one nitrogen atom. The nitrogen atom is part of an amide functional group, which consists of a carbonyl (C=O) group bonded to a nitrogen atom.

Pyrrolidinones are commonly found in various natural and synthetic compounds, including pharmaceuticals, agrochemicals, and materials. They exhibit a wide range of biological activities, such as anti-inflammatory, antiviral, and anticancer properties. Some well-known drugs that contain pyrrolidinone rings include the pain reliever tramadol, the muscle relaxant cyclobenzaprine, and the antipsychotic aripiprazole.

Pyrrolidinones can be synthesized through various chemical reactions, such as the cyclization of γ-amino acids or the reaction of α-amino acids with isocyanates. The unique structure and reactivity of pyrrolidinones make them valuable intermediates in organic synthesis and drug discovery.

Peptide YY (PYY) is a small peptide hormone consisting of 36 amino acids, that is released by the L cells in the intestinal epithelium in response to feeding. It is a member of the neuropeptide Y (NPY) family and plays a crucial role in regulating appetite and energy balance.

After eating, PYY is released into the circulation and acts on specific receptors in the hypothalamus to inhibit food intake. This anorexigenic effect of PYY is mediated by its ability to decrease gastric emptying, reduce intestinal motility, and increase satiety.

PYY has also been shown to have effects on glucose homeostasis, insulin secretion, and inflammation, making it a potential therapeutic target for the treatment of obesity, diabetes, and other metabolic disorders.

I'm sorry for any confusion, but "Isoflurophate" does not appear to be a recognized term in medical or scientific literature. It is possible that there may be a spelling error or typo in the term you are looking for. If you meant "Isoflurane," which is a commonly used anesthetic in medical and surgical procedures, I can provide a definition for that.

Isoflurane: A volatile halogenated ether liquid used as an inhalational general anesthetic agent. It has a rapid onset and offset of action, making it useful for both induction and maintenance of anesthesia. Isoflurane is also known to have bronchodilatory properties, which can be beneficial in patients with reactive airway disease or asthma.

Thiazoles are organic compounds that contain a heterocyclic ring consisting of a nitrogen atom and a sulfur atom, along with two carbon atoms and two hydrogen atoms. They have the chemical formula C3H4NS. Thiazoles are present in various natural and synthetic substances, including some vitamins, drugs, and dyes. In the context of medicine, thiazole derivatives have been developed as pharmaceuticals for their diverse biological activities, such as anti-inflammatory, antifungal, antibacterial, and antihypertensive properties. Some well-known examples include thiazide diuretics (e.g., hydrochlorothiazide) used to treat high blood pressure and edema, and the antidiabetic drug pioglitazone.

Oligopeptides are defined in medicine and biochemistry as short chains of amino acids, typically containing fewer than 20 amino acid residues. These small peptides are important components in various biological processes, such as serving as signaling molecules, enzyme inhibitors, or structural elements in some proteins. They can be found naturally in foods and may also be synthesized for use in medical research and therapeutic applications.

Swainsonine is not a medical condition or disease, but rather a toxin that can cause a medical condition known as "locoism" in animals. Swainsonine is produced by certain plants, including some species of the genera Swainsona and Astragalus, which are commonly known as locoweeds.

Swainsonine inhibits an enzyme called alpha-mannosidase, leading to abnormal accumulation of mannose-rich oligosaccharides in various tissues and organs. This can result in a range of clinical signs, including neurological symptoms such as tremors, ataxia (loss of coordination), and behavioral changes; gastrointestinal symptoms such as diarrhea, weight loss, and decreased appetite; and reproductive problems.

Locoism is most commonly seen in grazing animals such as cattle, sheep, and horses that consume large quantities of locoweeds over an extended period. It can be difficult to diagnose and treat, and prevention through management practices such as rotational grazing and avoiding the introduction of toxic plants into pastures is often the best approach.

Diabetes Mellitus, Type 2 is a metabolic disorder characterized by high blood glucose (or sugar) levels resulting from the body's inability to produce sufficient amounts of insulin or effectively use the insulin it produces. This form of diabetes usually develops gradually over several years and is often associated with older age, obesity, physical inactivity, family history of diabetes, and certain ethnicities.

In Type 2 diabetes, the body's cells become resistant to insulin, meaning they don't respond properly to the hormone. As a result, the pancreas produces more insulin to help glucose enter the cells. Over time, the pancreas can't keep up with the increased demand, leading to high blood glucose levels and diabetes.

Type 2 diabetes is managed through lifestyle modifications such as weight loss, regular exercise, and a healthy diet. Medications, including insulin therapy, may also be necessary to control blood glucose levels and prevent long-term complications associated with the disease, such as heart disease, nerve damage, kidney damage, and vision loss.

Cyclic nucleotide phosphodiesterases (PDEs) are a family of enzymes that regulate intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are important second messengers involved in various cellular processes.

Type 4 phosphodiesterases (PDE4) specifically hydrolyze cAMP and play a crucial role in regulating its intracellular concentration. PDE4 is widely expressed in many tissues, including the brain, heart, lungs, and immune system. It is involved in various physiological functions such as smooth muscle relaxation, neurotransmission, and inflammation.

PDE4 inhibitors have been developed as therapeutic agents for a variety of diseases, including asthma, chronic obstructive pulmonary disease (COPD), and depression. These drugs work by increasing intracellular cAMP levels, which can lead to bronchodilation, anti-inflammatory effects, and mood regulation. However, PDE4 inhibitors may also have side effects such as nausea, vomiting, and diarrhea, which limit their clinical use.

Proline is an organic compound that is classified as a non-essential amino acid, meaning it can be produced by the human body and does not need to be obtained through the diet. It is encoded in the genetic code as the codon CCU, CCC, CCA, or CCG. Proline is a cyclic amino acid, containing an unusual secondary amine group, which forms a ring structure with its carboxyl group.

In proteins, proline acts as a structural helix breaker, disrupting the alpha-helix structure and leading to the formation of turns and bends in the protein chain. This property is important for the proper folding and function of many proteins. Proline also plays a role in the stability of collagen, a major structural protein found in connective tissues such as tendons, ligaments, and skin.

In addition to its role in protein structure, proline has been implicated in various cellular processes, including signal transduction, apoptosis, and oxidative stress response. It is also a precursor for the synthesis of other biologically important compounds such as hydroxyproline, which is found in collagen and elastin, and glutamate, an excitatory neurotransmitter in the brain.

Glucagon is a hormone produced by the alpha cells of the pancreas. Its main function is to regulate glucose levels in the blood by stimulating the liver to convert stored glycogen into glucose, which can then be released into the bloodstream. This process helps to raise blood sugar levels when they are too low, such as during hypoglycemia.

Glucagon is a 29-amino acid polypeptide that is derived from the preproglucagon protein. It works by binding to glucagon receptors on liver cells, which triggers a series of intracellular signaling events that lead to the activation of enzymes involved in glycogen breakdown.

In addition to its role in glucose regulation, glucagon has also been shown to have other physiological effects, such as promoting lipolysis (the breakdown of fat) and inhibiting gastric acid secretion. Glucagon is often used clinically in the treatment of hypoglycemia, as well as in diagnostic tests to assess pancreatic function.

Enzyme inhibitors are substances that bind to an enzyme and decrease its activity, preventing it from catalyzing a chemical reaction in the body. They can work by several mechanisms, including blocking the active site where the substrate binds, or binding to another site on the enzyme to change its shape and prevent substrate binding. Enzyme inhibitors are often used as drugs to treat various medical conditions, such as high blood pressure, abnormal heart rhythms, and bacterial infections. They can also be found naturally in some foods and plants, and can be used in research to understand enzyme function and regulation.

A Glucose Tolerance Test (GTT) is a medical test used to diagnose prediabetes, type 2 diabetes, and gestational diabetes. It measures how well your body is able to process glucose, which is a type of sugar.

During the test, you will be asked to fast (not eat or drink anything except water) for at least eight hours before the test. Then, a healthcare professional will take a blood sample to measure your fasting blood sugar level. After that, you will be given a sugary drink containing a specific amount of glucose. Your blood sugar levels will be measured again after two hours and sometimes also after one hour.

The results of the test will indicate how well your body is able to process the glucose and whether you have normal, impaired, or diabetic glucose tolerance. If your blood sugar levels are higher than normal but not high enough to be diagnosed with diabetes, you may have prediabetes, which means that you are at increased risk of developing type 2 diabetes in the future.

It is important to note that a Glucose Tolerance Test should be performed under the supervision of a healthcare professional, as high blood sugar levels can be dangerous if not properly managed.

3',5'-Cyclic-AMP (cyclic adenosine monophosphate) phosphodiesterases are a group of enzymes that catalyze the breakdown of cyclic AMP to 5'-AMP. These enzymes play a crucial role in regulating the levels of intracellular second messengers, such as cyclic AMP, which are involved in various cellular signaling pathways.

There are several subtypes of phosphodiesterases (PDEs) that specifically target cyclic AMP, including PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, and PDE10. Each subtype has distinct regulatory and catalytic properties, allowing for specific regulation of cyclic AMP levels in different cellular compartments and signaling pathways.

Inhibition of these enzymes can lead to an increase in intracellular cyclic AMP levels, which can have therapeutic effects in various diseases, such as cardiovascular disease, pulmonary hypertension, and central nervous system disorders. Therefore, PDE inhibitors are a valuable class of drugs for the treatment of these conditions.

Incretins are hormones that are released from the gut in response to food intake, with two major types being glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate the pancreas to produce insulin, suppress the release of glucagon from the pancreas, slow down gastric emptying, and promote satiety. Incretins play a significant role in regulating blood sugar levels after meals, and medications that mimic or enhance incretin action are used in the treatment of type 2 diabetes.

In the context of medicine and pharmacology, "kinetics" refers to the study of how a drug moves throughout the body, including its absorption, distribution, metabolism, and excretion (often abbreviated as ADME). This field is called "pharmacokinetics."

1. Absorption: This is the process of a drug moving from its site of administration into the bloodstream. Factors such as the route of administration (e.g., oral, intravenous, etc.), formulation, and individual physiological differences can affect absorption.

2. Distribution: Once a drug is in the bloodstream, it gets distributed throughout the body to various tissues and organs. This process is influenced by factors like blood flow, protein binding, and lipid solubility of the drug.

3. Metabolism: Drugs are often chemically modified in the body, typically in the liver, through processes known as metabolism. These changes can lead to the formation of active or inactive metabolites, which may then be further distributed, excreted, or undergo additional metabolic transformations.

4. Excretion: This is the process by which drugs and their metabolites are eliminated from the body, primarily through the kidneys (urine) and the liver (bile).

Understanding the kinetics of a drug is crucial for determining its optimal dosing regimen, potential interactions with other medications or foods, and any necessary adjustments for special populations like pediatric or geriatric patients, or those with impaired renal or hepatic function.

Insulin is a hormone produced by the beta cells of the pancreatic islets, primarily in response to elevated levels of glucose in the circulating blood. It plays a crucial role in regulating blood glucose levels and facilitating the uptake and utilization of glucose by peripheral tissues, such as muscle and adipose tissue, for energy production and storage. Insulin also inhibits glucose production in the liver and promotes the storage of excess glucose as glycogen or triglycerides.

Deficiency in insulin secretion or action leads to impaired glucose regulation and can result in conditions such as diabetes mellitus, characterized by chronic hyperglycemia and associated complications. Exogenous insulin is used as a replacement therapy in individuals with diabetes to help manage their blood glucose levels and prevent long-term complications.

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

Hydrolysis is a chemical process, not a medical one. However, it is relevant to medicine and biology.

Hydrolysis is the breakdown of a chemical compound due to its reaction with water, often resulting in the formation of two or more simpler compounds. In the context of physiology and medicine, hydrolysis is a crucial process in various biological reactions, such as the digestion of food molecules like proteins, carbohydrates, and fats. Enzymes called hydrolases catalyze these hydrolysis reactions to speed up the breakdown process in the body.

A kidney, in medical terms, is one of two bean-shaped organs located in the lower back region of the body. They are essential for maintaining homeostasis within the body by performing several crucial functions such as:

1. Regulation of water and electrolyte balance: Kidneys help regulate the amount of water and various electrolytes like sodium, potassium, and calcium in the bloodstream to maintain a stable internal environment.

2. Excretion of waste products: They filter waste products from the blood, including urea (a byproduct of protein metabolism), creatinine (a breakdown product of muscle tissue), and other harmful substances that result from normal cellular functions or external sources like medications and toxins.

3. Endocrine function: Kidneys produce several hormones with important roles in the body, such as erythropoietin (stimulates red blood cell production), renin (regulates blood pressure), and calcitriol (activated form of vitamin D that helps regulate calcium homeostasis).

4. pH balance regulation: Kidneys maintain the proper acid-base balance in the body by excreting either hydrogen ions or bicarbonate ions, depending on whether the blood is too acidic or too alkaline.

5. Blood pressure control: The kidneys play a significant role in regulating blood pressure through the renin-angiotensin-aldosterone system (RAAS), which constricts blood vessels and promotes sodium and water retention to increase blood volume and, consequently, blood pressure.

Anatomically, each kidney is approximately 10-12 cm long, 5-7 cm wide, and 3 cm thick, with a weight of about 120-170 grams. They are surrounded by a protective layer of fat and connected to the urinary system through the renal pelvis, ureters, bladder, and urethra.

Membrane proteins are a type of protein that are embedded in the lipid bilayer of biological membranes, such as the plasma membrane of cells or the inner membrane of mitochondria. These proteins play crucial roles in various cellular processes, including:

1. Cell-cell recognition and signaling
2. Transport of molecules across the membrane (selective permeability)
3. Enzymatic reactions at the membrane surface
4. Energy transduction and conversion
5. Mechanosensation and signal transduction

Membrane proteins can be classified into two main categories: integral membrane proteins, which are permanently associated with the lipid bilayer, and peripheral membrane proteins, which are temporarily or loosely attached to the membrane surface. Integral membrane proteins can further be divided into three subcategories based on their topology:

1. Transmembrane proteins, which span the entire width of the lipid bilayer with one or more alpha-helices or beta-barrels.
2. Lipid-anchored proteins, which are covalently attached to lipids in the membrane via a glycosylphosphatidylinositol (GPI) anchor or other lipid modifications.
3. Monotopic proteins, which are partially embedded in the membrane and have one or more domains exposed to either side of the bilayer.

Membrane proteins are essential for maintaining cellular homeostasis and are targets for various therapeutic interventions, including drug development and gene therapy. However, their structural complexity and hydrophobicity make them challenging to study using traditional biochemical methods, requiring specialized techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and single-particle cryo-electron microscopy (cryo-EM).

I'm sorry for any confusion, but "Rats, Zucker" is not a standard medical term or abbreviation in human medicine. It seems to be an incorrect combination of two terms from the field of laboratory animal science.

1. "Rats" are commonly used laboratory animals.
2. "Zucker" is a surname and also refers to a strain of laboratory rats, specifically the Zucker Diabetic Fatty (ZDF) rat, which is a model for studying type 2 diabetes mellitus.

If you have any questions related to human medicine or healthcare, I would be happy to help clarify those for you.

McIntosh CH, Demuth HU, Pospisilik JA, Pederson R (June 2005). "Dipeptidyl peptidase IV inhibitors: how do they work as new ... "Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine". ... Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme ... Abrahami D, Douros A, Yin H, Yu OH, Renoux C, Bitton A, Azoulay L (March 2018). "Dipeptidyl peptidase-4 inhibitors and ...
"Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes", Diabetes and ... "Prolyl peptidase related to dipeptidyl peptidase IV: Potential of specific inhibitors in drug discovery", Current Topics in ... "Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)", Current Topics in Medicinal Chemistry, 7 (6): 597-608, doi: ... "Dipeptidyl peptidase IV inhibitors: The next generation of new promising therapies for the management of type 2 diabetes", ...
May 2004). "Heterocycle-Fused Cyclohexylglycine Derivatives as Novel Dipeptidyl Peptidase-IV Inhibitors". ChemInform. 35 (20). ... In 2006, Parmee was one of the lead investigators in the discovery of the selective Dipeptidyl peptidase-4 inhibitor ... Karim, Sufia; Parmee, Emma R; Thomas, Eric J (May 1991). "Milbemycin synthesis: synthesis of 6β-hydroxy-3,4-dihydromilbemycin E ... Archived from the original on 4 November 2015. Retrieved 19 November 2015. "Emma Parmee, Vice President, Discovery Chemistry, ...
GLP-1 analogs resulted in weight loss and had more gastrointestinal side-effects, while in general dipeptidyl peptidase-4 (DPP- ... over sulfonylureas and α-glucosidase inhibitors. However, they are less preferred than GLP-1 agonists or SGLT2 inhibitors, ... However, weight gain and/or hypoglycemia have been observed when dipeptidyl peptidase-4 inhibitors were used with sulfonylureas ... January 2009 National Prescribing Service (August 1, 2010). "Dipeptidyl peptidase-4 inhibitors ('gliptins') for type 2 diabetes ...
The MEROPS online database for peptidases and their inhibitors: S09.003 Dipeptidyl-Peptidase+IV at the U.S. National Library of ... "Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction". ... was called dipeptidyl peptidase IV [DP IV]. The protein encoded by the DPP4 gene is an enzyme expressed on the surface of most ... "CD26/Dipeptidyl Peptidase IV in Lymphocyte Growth Regulation". Cellular Peptidases in Immune Functions and Diseases. Advances ...
"RCSB PDB - 3F8S: Crystal structure of dipeptidyl peptidase IV in complex with inhibitor". Sharma R, Sun H, Piotrowski DW, Ryder ... orally active dipeptidyl peptidase IV inhibitor". Bioorganic & Medicinal Chemistry Letters. 19 (7): 1991-1995. doi:10.1016/j. ... a Dipeptidyl Peptidase Inhibitor, in Rat, Dog and Human". Drug Metabolism and Disposition. 40 (11): 2143-2161. doi:10.1124/dmd. ... It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors (also called gliptins). It was discovered and developed through ...
McIntosh CH, Demuth HU, Pospisilik JA, Pederson R (June 2005). "Dipeptidyl peptidase IV inhibitors: how do they work as new ... a once weekly dipeptidyl peptidaseIV (DPP‐4) inhibitor, in patients with renal impairment" (PDF). Clin Pharmacol Ther. Merck ... Dipeptidyl peptidase-4 inhibitor Alogliptin Linagliptin Saxagliptin Sitagliptin Vildagliptin v t e (Articles with short ... Dipeptidyl peptidase-4 inhibitors, Fluoroarenes, Sulfonamides, Phenylethanolamine ethers, Merck & Co. brands, All stub articles ...
Parsa, Kishore Vl; Pal, Manojit (2011-08-01). "Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief ...
Dipeptidyl peptidase-4 inhibitors inhibit dipeptidyl peptidase-4 and thus reduce glucagon and blood glucose levels. DPP-4 ... SGLT-2 inhibitors There are combinations of metformin with dapagliflozin, empagliflozin and canagliflozin. Sulfonylureas act by ... March 2022). "Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis". ... complex IV-mediated inhibition of the GPD2 variant of mitochondrial glycerol-3-phosphate dehydrogenase (thereby reducing ...
May 2007). "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". ... Alogliptin is a dipeptidyl peptidase-4 inhibitor that decreases blood sugar similar to the other. Adverse events include mild ... Dipeptidyl peptidase-4 inhibitors, Nitriles, Piperidines, Ureas, Imides, Pyrimidinediones, Enantiopure drugs, Takeda ... "DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain". U.S. Food and Drug ...
"A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site". ... It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins". It was created by ... Dipeptidyl peptidase-4 inhibitors, Pyrazoles, Piperazines, All stub articles, Gastrointestinal system drug stubs). ... Teneligliptin has unique J shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme ...
... orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes". Journal of Medicinal Chemistry. 48 (15 ... Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP and the degradation of ... Mentlein R, Gallwitz B, Schmidt WE (June 1993). "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon- ... Scott AS, Gregory SJ, Sergei K, Shelly AR, Truc V, Robert EW (2009). "Preparation of Saxagliptin, a Novel DPP-IV Inhibitor". ...
December 2005). "Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy ... It is in the dipeptidyl peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing ... Sitagliptin works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). This enzyme breaks down the incretins GLP ... May 2016). "Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and ...
It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins". Graul AI, Lupone B, ... as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry. 19 (23): 7221-7. doi:10.1016/j.bmc.2011.09.043. ... Dipeptidyl peptidase-4 inhibitors, Nitriles, Pyrazolopyrimidines, All stub articles, Gastrointestinal system drug stubs). ...
Drucker DJ, Nauck MA (November 2006). "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase- ... Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4) and are members of the glucagon peptide ... Several DPP-4 inhibitors that can be taken orally as tablets have been developed. The incretin effect describes the phenomenon ... 4 (6): 525-536. doi:10.1016/s2213-8587(15)00482-9. ISSN 2213-8587. PMID 26876794. Rehfeld JF (2018-07-16). "The Origin and ...
"Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV". Nature Biotechnology. 15 ... glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors". Diabetes, Obesity & Metabolism. 9 (Suppl 1): ...
Drucker, D. J.; Nauck, M. A. (2006). "The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 ... "Four Nova Scotians among Order of Canada honourees". The Chronicle-Herald, 1 July 2015. "National Academy of Medicine Elects ... inhibitors in type 2 diabetes". The Lancet. 368 (9548): 1696-705. doi:10.1016/S0140-6736(06)69705-5. PMID 17098089. S2CID ...
Immune regulating proteins found in prostasomes include: amino-peptidase N (CD13); dipeptidyl-peptidase IV (CD26); ... inhibitor of MAC) and complement regulatory membrane cofactor protein (CD46). Prostasomes also contain high levels of the ... Arienti G, Polci A, Carlini E, Palmerini CA (June 1997). "Transfer of CD26/dipeptidyl peptidase IV (E.C. 3.5.4.4) from ... "Prostasomes from four different species are able to produce extracellular adenosine triphosphate (ATP)". Biochimica et ...
Drucker DJ, Nauck MA (November 2006). "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase- ... Zverkov IV, Vinogradov VA, Smagin VG (October 1983). "[Endorphin-containing cells in the gastric antral mucosa in duodenal ... IV. Functional implications of bitter taste receptors in gastrointestinal chemosensing". American Journal of Physiology. ... 78 (4): 1087-108. doi:10.1152/physrev.1998.78.4.1087. PMID 9790570. Solcia E, Capella C, Buffa R, Usellini L, Fiocca R, ...
Evogliptin is a dipeptidyl peptidase-4 inhibitor developed by Dong-A ST. Fimasartan is a non-peptide angiotensin II receptor ... Udenafil is a PDE5 inhibitor developed by Dong-A Pharmaceutical to treat erectile dysfunction. Polmacoxib is a nonsteroidal ... Implemented in 1956, Juche follows the four principles of "autonomy in ideology, independence in politics, self-sufficiency in ... Gemigliptin is a dipeptidyl peptidase-4 inhibitor developed by LG Life Sciences to treat hyperglycemia in patients with type 2 ...
Inagaki N, Onouchi H, Sano H, Funao N, Kuroda S, Kaku K (February 2014). "SYR-472, a novel once-weekly dipeptidyl peptidase-4 ( ... highlighted the good glycaemic efficacy and safety of this molecule as compared to peer DPP4 inhibitors which have to be taken ... Dutta D, Mohindra R, Surana V, Sharma S (March 2022). "Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor ... It is a highly selective dipeptidyl peptidase-4 inhibitor that is typically used as an add on treatment when the first line ...
Mentlein R, Gallwitz B, Schmidt WE (June 1993). "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon- ... inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to ... Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (May 2004). "Inhibition of dipeptidyl peptidase-4 ... Development of dipeptidyl peptidase-4 inhibitors Dipeptidyl peptidase-4 (CD26) WHO International Working Group for Drug ...
... (INN; trade names Suganon, Evodine) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or " ... demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and ... "Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta- ... Dipeptidyl peptidase-4 inhibitors, Fluoroarenes, Piperazines, Tert-butyl compounds, All stub articles, Gastrointestinal system ...
Quran 58:2-4 Fasting is primarily an exercise of devotion to willingly renounce oneself, for a definite period of time, from ... Fasting is one of the alternatives proved to reduce the DPP-4 level and activate the dipeptidyl peptidase-4 inhibitors and so, ...
Details of Merck's major products are as follows: Januvia (sitagliptin) is a dipeptidyl peptidase IV inhibitor for the ... There has been some concern that treatment with Januvia and other DPP-IV inhibitors may be associated with a modestly increased ... "Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to ... In 2017, Merck bought the PARP inhibitor Lynparza from AstraZeneca. In April 2017, Merck Animal Health acquired Vallée S.A., a ...
... is a dipeptidyl peptidase-4 inhibitor that works by increasing the production of insulin and decreasing the ... Dipeptidyl peptidase-4 inhibitors, Eli Lilly and Company brands, Piperidines, Quinazolines, Xanthines, Wikipedia medicine ... "DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain". U.S. Food and Drug ... Linagliptin belongs to a class of drugs called DPP-4 inhibitors. Linagliptin is the international nonproprietary name (INN). ...
One study has also found some activity as a Dipeptidyl peptidase-4 inhibitor and prolyl oligopeptidase inhibitor at high ... concentrations (in the millimolar range). It is an effective inhibitor in laboratory models of prostate and skin cancers. As an ... 4 (2): 72-74. doi:10.1016/j.phytol.2010.08.004. PMC 3099468. PMID 21617767. Stork G, Uyeo S, Wakamatsu T, Grieco P, Labovitz J ... 20 (4): 279-87. doi:10.1002/ptr.1852. PMID 16557610. S2CID 34485412. Mannowetz N, Miller MR, Lishko PV (May 2017). "Regulation ...
Dipeptidyl peptidase-4 inhibitor alone or in combination with basal insulin can be used as a treatment for hyperglycemia with ... protease inhibitors, L-asparaginase, and antipsychotics. The acute administration of stimulants such as amphetamines typically ... where 4 mmol/L or 80 mg/dL is "optimal".) A subject with a consistent range above 7 mmol/L or 126 mg/dL is generally held to ... 40 (4): 509-517. doi:10.2337/dc16-0989. PMC 5864102. PMID 28325798. "diabetes FAQ: general (part 1 of 5)Section - What are mg/ ...
Dipeptidyl peptidase IV (DPP-4) inhibitors (sitagliptin): helps with improving blood sugar levels by decreasing the action of ... HMG-CoA reductase inhibitors, also called "statins," effectively lower levels of low-density lipoprotein, cholesterol and ... Heart medications: Angiotensin-converting enzyme (ACE) inhibitors, diuretics, digoxin and beta-blockers may help with the ... Presentation 15 years - adulthood: 2 major and 2 minor criteria or 1 major and 4 minor criteria. Major criteria are: ALMS1 ...
... and Dipeptidyl Peptidase 4 Inhibitors with All-Cause Mortality in Patients with Type 2 Diabetes". JAMA. 319 (15): 1580-1591. ... and ertugliflozin should be stopped at least four days before scheduled surgery. Symptoms of ketoacidosis include nausea, ... Dapagliflozin is an example of an SGLT-2 inhibitor, it is a competitive, highly selective inhibitor of SGLT. It acts via ... SGLT2 inhibitors increase circulating ketone body concentrations. The cardioprotective effects of SGLT2 inhibitors have been ...

No FAQ available that match "dipeptidyl peptidase iv inhibitors"